EQ•benzinga•
Equillium Announces Results of the Phase 3 EQUATOR Study Of Itolizumab, Showing Treatment With Itolizumab Did Not Improve Complete Or Overall Response Rates At Day 29; Says Statistically Significant And Clinically Meaningful Benefit In Longer-term Outcome
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 27, 2025 by benzinga